Insights from populations at risk for the future development of classified rheumatoid arthritis

Rheumatic Disease Clinics of North America

Volumn 40, Issue 4, 2014, Pages 605-620

  Holers, V Michael ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Autoantibodies; Biomarkers; Dietary factors; Epidemiology; Imaging; Preclinical rheumatoid arthritis; Prediction; Prevention

Indexed keywords

CHEMOKINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYTOKINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; OMEGA 3 FATTY ACID; RHEUMATOID FACTOR; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; EPITOPE;

ANTIBODY TITER; ARTHRALGIA; BONE EROSION; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CYTOKINE RELEASE; DISEASE COURSE; DISEASE PREDISPOSITION; ECHOGRAPHY; ENVIRONMENTAL EXPOSURE; FIRST DEGREE RELATIVE; GENETIC ASSOCIATION; GENETIC RISK; GENOMICS; HIGH RISK POPULATION; HUMAN; LUNG DISEASE; METABOLOMICS; MICROBIOME; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; PERIODONTITIS; PORPHYROMONAS GINGIVALIS; REVIEW; RHEUMATOID ARTHRITIS; ASYMPTOMATIC DISEASE; GENETICS; IMMUNOLOGY; RISK;

ARTHRITIS, RHEUMATOID; ASYMPTOMATIC DISEASES; AUTOANTIBODIES; DISEASE PROGRESSION; EPITOPES; HUMANS; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; RISK;

EID: 84908079341     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.07.003     Document Type: Review

References (104)

1. Fuchs H.A., Sergent J.S. Rheumatoid arthritis: the clinical picture. Arthritis and allied conditions: a textbook of rheumatology 1997, 1041-1070. Williams and Wilkins, Baltimore (MD). 13th edition. W.J. Koopman (Ed.).
2. Lee D.M., Weinblatt M.E. Rheumatoid arthritis. Lancet 2001, 359:903-911.
3. Schellekens G.A., Visser H., de Jong B.A., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43:155-163.
4. van Venrooij W.J., Pruijn G.J. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2000, 2:249-251.
5. Bas S., Genevay S., Meyer O., et al. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 2003, 42:677-680.
6. Klareskog L., Malmstrom V., Lundberg K., et al. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 2011, 23:92-98.
7. Padyukov L., Silva C., Stolt P., et al. Agene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004, 50:3085-3092.
8. Deane K.D., O'Donnell C.I., Hueber W., et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum 2010, 62:3161-3172.
9. Aho K., Heliovaara M., Maatela J., et al. Rheumatoid factors antedating clinical rheumatoid arthritis. JRheumatol 1991, 18:1282-1284.
10. Aho K., Paluso T., Heliovaara M., et al. Antifilaggrin antibodies within "normal" range predict rheumatoid arthritis in a linear fashion. JRheumatol 2000, 27:2743-2746.
11. Berglin E., Padyukov L., Sundin U., et al. Acombination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with the future onset of rheumatoid arthritis. Arthritis Res Ther 2004, 6:R303-R308.
12. del Puente A., Knowler W.C., Pettitt D.J., et al. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum 1988, 31:1239-1244.
13. Nielen M.M., van Schaardenburg D., Reesink H.W., et al. Increased levels of C-Reactive Protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004, 50:2423-2427.
14. Nielen M.M., van Schaardenburg D., Reesink H.W., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis. Arthritis Rheum 2004, 50:380-386.
15. Rantapaa Dahlqvist S., de Jong B.A., Hallmans G., et al. Antibodies against citrullinated peptides (CCP) predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2701-2705.
16. Karlson E.W., Chisnik L.B., Tworoger S.S., et al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum 2009, 60:641-652.
17. Deane K.D., Norris J.M., Holers V.M. Pre-clinical rheumatoid arthritis: identification, evaluation and future directions for investigation. Rheum Dis Clin North Am 2010, 13:236-241.
18. Gerlag D.M., Raza K., van Baarsen L.G., et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for risk factors for rheumatoid arthritis. Ann Rheum Dis 2012, 71:638-641.
19. Raza K., Breese M., Nightingale P., et al. Predictive value of antibodies to cycliccitrullinated peptide in patients with very early inflammatory arthritis. JRheumatol 2005, 32:203-207.
20. Silman A.J., Ollier B., Mageed R.A. Rheumatoid factor detection in the unaffected first degree relatives in families with multicase rheumatoid arthritis. JRheumatol 1991, 18:512-515.
21. Silman A.J. Epidemiology of rheumatoid arthritis. APMIS 1994, 102:721-728.
22. El-Gabalawy H.S., Robinson D.B., Smolik I., et al. Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum 2012, 64:1720-1729.
23. Kolfenbach J.R., Deane K.D., Derber L.A., et al. Aprospective approach to investigating the natural history of pre-clinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. Arthritis Care Res 2009, 61:1735-1741.
24. Bos W.H., Dijkmans B.A., Boers M., et al. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomized trial. Ann Rheum Dis 2010, 69:571-574.
25. van de Sande M.G., de Hair M.J., van der Leij C., et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011, 70:772-777.
26. van de Stadt L.A., van der Horst A.R., de Koning M.H., et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011, 70:128-133.
27. Deane K.D., Striebich C., Goldstein B.L., et al. Identification of undiagnosed inflammatory arthritis in a community health fair screen. Arthritis Care Res 2009, 61:1642-1649.
28. Willis V.C., Demoruelle M.K., Derber L.A., et al. Sputa autoantibodies in patients with established rheumatoid arthritis and subjects at-risk for future clinically apparent disease. Arthritis Rheum 2013, 65:2545-2554.
29. Aletaha D., Neogi T., Silman A.J., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
30. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1998, 31:314-324.
31. Coenen D., Verschueren P., Westhovens R., et al. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007, 53:498-504.
32. Demoruelle M.K., Deane K.D. Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance. Curr Rheumatol Rep 2011, 13:421-430.
33. Goldbach-Mansky R., Lee J., McCoy A., et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res Ther 2000, 2:236-243.
34. Demoruelle M.K., Parish M.C., Derber L.A., et al. Performance of anti-cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum 2013, 65:2243-2252.
35. Brink M., Hansson M., Mathsson L., et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to the development of rheumatoid arthritis. Arthritis Rheum 2013, 65:899-910.
36. Hueber W., Kidd B.A., Tomooka B.H., et al. Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 2005, 52:2645-2655.
37. Shi J., Knevel R., Suwannalai P., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011, 108:17372-17377.
38. Vossenaar E.R., Despres N., LaPointe E., et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6:R142.
39. Hassfeld W., Steiner G., Graninger W., et al. Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 1993, 32:199-203.
40. Harris M.L., Darrah E., Lam G.K., et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 2008, 58:1958-1967.
41. Sokolove J., Bromberg R., Deane K.D., et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 2012, 7:e35296.
42. El-Gabalawy H.S., Robinson D.B., Hart D., et al. Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American native population with rheumatoid arthritis and their first-degree relatives. JRheumatol 2009, 36:1130-1135.
43. Arlestig L., Mullazehi M., Kokkonen H., et al. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden. Ann Rheum Dis 2012, 71:825-829.
44. Young K.A., Deane K.D., Derber L.A., et al. Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis. Arthritis Rheum 2013, 65:1995-2004.
45. Barra L., Scinocca M., Saunders S., et al. Anti-citrullinated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients. Arthritis Rheum 2013, 65:1439-1447.
46. Suwannalai P., van de Stadt L.A., Radner H., et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2012, 64:1323-1328.
47. Trouw L.A., Haisma E.M., Levarht E.W., et al. Anti-cyclic peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009, 60:1923-1931.
48. Ercan A., Cui J., Chatterton D.E., et al. IgG galactosylation aberrancy precedes disease onset, correlates with disease activity and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum 2010, 62:2238-2248.
49. Scherer H.U., van der Woude D., Ioan-Facsinay A., et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 2010, 62:1620-1629.
50. Barra L., Bykerk V.P., Pope J.E., et al. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. JRheumatol 2013, 40:1259-1267.
51. James E., Rieck M., Pieper J., et al. Citrulline specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheum 2014, 66(7):1712-1722.
52. Law S.C., Street S., Yu C.H., et al. T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Res Ther 2012, 14:R118.
53. Kerkaman P.F., Rombouts Y., van der Voort E., et al. Circulating plasmablasts/plasma cells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Ann Rheum Dis 2013, 72:1259-1263.
54. Amara K., Steen J., Murray F., et al. Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition. JExp Med 2013, 210:445-455.
55. Menard L., Samuels J., Meffre E. Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum 2011, 63:1237-1245.
56. Samuels J., Ng Y.S., Coupillaud C.P., et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. JExp Med 2005, 210:1659-1667.
57. Liubchenko G.A., Appleberry H.C., Striebich C.C., et al. Rheumatoid arthritis is associated with signaling alterations in naturally occurring autoreactive B-lymphocytes. JAutoimmun 2013, 40:111-121.
58. Spits H., Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 2012, 30:647-675.
59. Hueber W., Tomooka B.H., Zhao X., et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007, 66:712-719.
60. Jorgensen K.T., Wiik A., Pedersen M., et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2008, 67:860-866.
61. Kokkonen H., Soderstrom I., Rocklov J., et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum 2010, 62:383-391.
62. Hughes-Austin J., Deane K.D., Derber L.A., et al. Multiple cytokines and chemokines are associated with rheumatoid arthritis-related autoimmunity in first-degree relatives without rheumatoid arthritis: studies of the Aetiology of Rheumatoid Arthritis (SERA). Ann Rheum Dis 2012, 72:901-907.
63. Nepom G.T., Nepom B.S. Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen phenotyping. Rheum Dis Clin North Am 1992, 18:785-792.
64. Begovich A.B., Carlton V.E., Honigberg L.A., et al. Amissense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004, 75:330-337.
65. Viatte S., Plant D., Raychaudhuri S. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013, 9:141-153.
66. Bax M., van Heemst J., Huizinga T.W., et al. Genetics of rheumatoid arthritis: what have we learned?. Immunogenetics 2011, 63:459-466.
67. Hu X., Kim H., Stahl E., et al. Integrating autoimmune risk loci with gene-expression data identifies specific pathogenic immune cell subsets. Am J Hum Genet 2011, 89:496-506.
68. Gregersen P.K., Amos C.I., Lee A.T., et al. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet 2009, 41:820-823.
69. Klareskog L., Stolt P., Lundberg K., et al. Anew model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54:38-46.
70. Mahdi H., Fisher B.A., Kallberg H., et al. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. Nat Genet 2009, 41:1319-1324.
71. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
72. Nakano K., Whitaker J.W., Boyle D.L., et al. DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis 2013, 72:110-117.
73. Tan Y.K., Ostergaard M., Conaghan P.G. Imaging tools in rheumatoid arthritis: ultrasound vs magnetic resonance imaging. Rheumatology 2012, 51(Suppl):vii36-vii42.
74. de Hair M.J., van de Sande M.G., Ramwadhdoebe T.H., et al. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheum 2014, 66:513-522.
75. Freeston J.E., Wakefield R.J., Conaghan P.G., et al. Adiagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis 2010, 69:417-419.
76. Karlson E.W., Deane K.D. Environmental and gene-environment interactions and risk of rheumatoid arthritis. Rheum Dis Clin North Am 2012, 38:405-426.
77. James M., Proudman S., Cleland L. Fish oil and rheumatoid arthritis: past, present and future. Proc Nutr Soc 2010, 69:316-323.
78. Bhatia S.S., Majka D.S., Kittelson J.M., et al. Rheumatoid factor seropositivity is inversely associated with oral contraceptive use in women without arthritis. Ann Rheum Dis 2007, 66:267-269.
79. Feser M., Derber L.A., Deane K.D., et al. Plasma 25,OH vitamin D levels are not associated with rheumatoid arthritis-related autoantibodies in individuals at elevated risk for rheumatoid arthritis. JRheumatol 2009, 36:943-946.
80. Gan R.W., Deane K.D., Zerbe G.O., et al. Relationship between air pollution and positivity of RA-related autoantibodies in individuals without established RA: a report on SERA. Ann Rheum Dis 2013, 72:2002-2005.
81. Gabriel S.E., Crowson C.S., O'Fallon W.M. Mortality in rheumatoid arthritis; have we made an impact in 4 decades. JRheumatol 1999, 26:2529-2533.
82. Goldring S.R. Periarticular bone changes in rheumatoid arthritis: pathophysiological implications and clinical utility. Ann Rheum Dis 2009, 68:297-299.
83. Schett G., Gravallese E.M. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 2012, 8:656-664.
84. Harre U., Georgess D., Bang H., et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. JClin Invest 2012, 122:1791-1802.
85. Kleyer A., Finzel S., Rech J., et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 2014, 73:854-860.
86. Metafratzi Z.M., Georgiadis A.N., Ioannidou C.V., et al. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol 2007, 38:338-344.
87. Demoruelle M.K., Weisman M.H., Simonian P.L., et al. Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity?. Arthritis Rheum 2012, 64:1756-1761.
88. Smit M.D., Westra J., Vissink A., et al. Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. Arthritis Res Ther 2012, 14:R222.
89. Wegner N., Wait R., Sroka A., et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and a-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010, 62:2662-2672.
90. Scher J.U., Ubeda C., Equinda M., et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum 2012, 64:3083-3094.
91. Wu H.J., Ivanov I., Darce J., et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010, 32:815-827.
92. Vaahtovuo J., Munukka E., Korkeamaki M., et al. Fecal microbiota in early rheumatoid arthritis. JRheumatol 2008, 35:1500-1505.
93. Scher J.U., Sczesnak A., Longman R.S., et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife (Cambridge) 2013, 2:e01202. 10.7554/eLife.01202.
94. Mikuls T.R., Thiele G.M., Deane K.D., et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum 2012, 64:3522-3530.
95. Young S.P., Kapoor S.R., Viant M.R., et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum 2013, 65:2015-2023.
96. Norris J.M., Barriga K., Klingensmith G., et al. Timing of initial cereal exposure in infancy and risk of islet cell autoimmunity. JAMA 2003, 290:1713-1720.
97. Arend W.P., Firestein G.S. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 2012, 8:573-576.
98. Klareskog L., Ronnelid J., Lundberg K., et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008, 26:651-675.
99. Zhao X., Okeke N.L., Sharpe O., et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res Ther 2008, 10:R94.
100. Sokolove J., Zhao X., Chandra P.E., et al. Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fc-gamma receptor. Arthritis Rheum 2011, 63:53-62.
101. Kuhn K.A., Kulik L., Tomooka B., et al. Antibodies to citrullinated proteins enhance tissue injury in experimental arthritis. JClin Invest 2006, 116:961-973.
102. Uysal H., Bockermann R., Nandakumar K.S., et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. JExp Med 2009, 206:449-462.
103. Cordova K.N., Willis V.C., Haskins K., et al. Acitrullinated fibrinogen-specific T cell line enhances autoimmune arthritis in a mouse model of rheumatoid arthritis. JImmunol 2013, 190:1457-1465.
104. Ytterberg A.J., Reynisdottir G., Ossipova E., et al. Identification of shared citrullinated immunological targets in the lungs and joints of patients with rheumatoid arthritis. Ann Rheum Dis 2012, 71:A19.